Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has reported a significant 41% quarter-over-quarter increase in NeXT Personal Dx volumes in Q4'25, exceeding previous expectations, which reflects the potential for continued growth driven by its commercial partnership with Tempus. The recent announcement of Medicare coverage and pricing for the NeXT Personal MRD test marks a pivotal moment, likely enhancing adoption rates and revenue generation, particularly in breast cancer diagnostics. Additionally, the demonstrated ability of NeXT Personal to detect minimal residual disease (MRD) in the critical 1-100 ppm range further establishes the test's value, reinforcing the company's prospects in the personalized medicine landscape.

Bears say

Personalis Inc's outlook is adversely impacted by a combination of slowing demand within the biopharmaceutical sector and operational challenges, culminating in a lowered revenue guidance for Q4 2025. The company's year-over-year revenue decline in pharmaceutical services, attributed to the conclusion of Moderna's melanoma trial enrollment, raises concerns regarding its capacity to sustain and grow its revenue streams. Additionally, persistent financial losses and the existence of debt on the balance sheet signal potential difficulties in maintaining profitability going forward, which could further challenge investor confidence in the stock.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.